PALO ALTO, Calif., January 5, 2022 / PRNewswire / - Neuvivo today announced the expansion of its management team and Board, adding Gregg fergus as Head of Strategy and Business Development and a new member of its Board of Directors. Gregg is the former President and COO of Ion Torrent, a market-leading company that pioneered an efficient and cost-effective approach to DNA sequencing and was sold to Life Technologies.
Gregg's previous executive positions include Chief Commercial Officer of Cellular Dynamics International and Senior Vice President of Global Sales and Operations at Affymetrix, Inc. He was a Resident Executive at RW Baird / Baird Venture Partners.
"We are delighted that Gregg is joining Neuvivo at this stage as we accelerate our drug development and capital raising activities," he said. Ari azhir, PhD, founder and CEO of Neuvivo. "Gregg brings strong business and operational skills and an impressive record of creating value, as well as a clear passion to help improve treatment options for patients with ALS."
From 2014 to 2020, Gregg was CEO and Chief Commercial Officer of 4Catalyzer, a Guilford, Connecticutstartup accelerator based on the democratization of healthcare and maximizing social impact. Gregg co-founded, led and served on the boards of 4Catalyzer companies and raised more than $ 800 million in Capital. Butterfly Network, QSi, and Hyperfine, all seeded by 4Catalyzer, went public in 2021.
"I am truly excited to join the distinguished team at Neuvivo and am passionate about providing life-changing treatments for ALS patients and their families," he said Gregg fergus. "Neuvivo has made significant progress in understanding ALS and developing a new drug candidate - now is the time to bring NP001 to commercialization."
Gregg is a UW-Madison alumnus with a Bacteriology degree and has remained involved in college as a strategic advisor for the Institute for Healthy Minds and the Wisconsin Institutes of Discovery. Gregg is a member of the AIQ Board, Verda Bio and LรM.
About Neuvivo: Neuvivo is a private, late-stage biopharmaceutical company focused on creating and delivering advanced treatments for ALS and other neurodegenerative diseases. The company was formed by successful scientists and industry leaders committed to improving the prognosis of patients diagnosed with ALS and a variety of diseases for which there are few current treatment options. For more information please visit: www.Neuvivo.com.
New Contact:
Jennifer larson
415 409 2729
[emailย protected]
SOURCE Neuvivo, Inc.
